Insights On Drug Development

  1. Advancing ADC Development: Overcoming Preclinical Challenges 9/23/2025

    Learn how to accelerate the journey of ADC candidates from early discovery to clinical development, enhancing the success rate of translating preclinical discoveries into effective cancer treatments.

  2. BxPC-3: Evaluating Responses To Standard Therapeutic Agents 9/23/2025

    Review multiple studies utilizing the BxPC-3 human pancreatic cancer model in subcutaneous (SC) NSG and NSG-dKO mouse models, evaluating a range of standard agents, vehicles, and delivery methods.

  3. Not A Trick Question: How Do You Know When You Have Adequately Established A Reliable Supply Chain? 9/23/2025

    Leave it to an Outsourced Pharma Live digital discussion to ask the questions others leave out. How much de-risking is too much? When can you sleep at night knowing your supply chains are as they should be, and you can fully rely on them? Oh, and we answer questions such as these as well.

  4. When To Consolidate CDMOs ... And When You Shouldn't 9/23/2025

    A supply chain expert with decades of experience says that "from a a pure supply chain perspective, we always try to "have universal drug substance, universal drug product and try to differentiate in packaging." But that doesn't always work out ... 

  5. The Criticality Of Biannual Overview Meetings With Your Suppliers 9/23/2025

    Daily communication and periodic project- and individual team-level meetings are important. But according to one outsourcing professional with decades of experience, do not overlook the importance of Biannual (or Quarterly) meetings to ensure outsourcing success.

  6. Avoid Complexity In Any Supply Chain 9/23/2025

    Mani Sundararajan, a former VP Tech Ops and Global Outsourcing executive at BMS, AstraZeneca, Shire and others, teaches us that despite the program or distance between you and your CDMOs, the key to success is to simplify outsourcing to the extent possible.

  7. Are There Countries You Should Avoid When Outsourcing? 9/23/2025

    The regulatory or political environment can be different for drug development and manufacturing in countries around the globe. Is that a reason to avoid some? Our expert has his doubts.

  8. Second Sourcing Is Natural ... Your Current CDMO Should Understand 9/23/2025

    Seasoned supply chain professionals say it is only natural to de-risk supply chains with sourcing materials and products at more than one external manufacturer ... no matter the insistence from the first external partner.

  9. Supply Chain Due Diligence Before Acquiring Bio Assets 9/23/2025

    Before an organization decides to acquire or in-license an asset for development, it's key to evaluate the chain of events and partners that progressed that asset to the point it is now at.

  10. Reactive, Proactive, Or Inherited? Managing Supply Chains 9/23/2025

    Lynn Cinelli, recent VP Global Biologics Supply Chain at Bristol Myers Squibb, provides her insights on selecting and managing external development and manufacturing partners.